KLP Kapitalforvaltning AS Takes Position in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO)

KLP Kapitalforvaltning AS bought a new position in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO - Free Report) in the fourth quarter, according to the company in its most recent disclosure with the SEC. The institutional investor bought 10,000 shares of the biopharmaceutical company's stock, valued at approximately $329,000.

Other large investors have also recently bought and sold shares of the company. KBC Group NV grew its holdings in Agios Pharmaceuticals by 30.5% during the 4th quarter. KBC Group NV now owns 2,615 shares of the biopharmaceutical company's stock worth $86,000 after acquiring an additional 611 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank lifted its holdings in shares of Agios Pharmaceuticals by 6.0% during the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 12,132 shares of the biopharmaceutical company's stock worth $539,000 after purchasing an additional 688 shares during the period. Atria Investments Inc grew its stake in shares of Agios Pharmaceuticals by 6.9% in the fourth quarter. Atria Investments Inc now owns 11,365 shares of the biopharmaceutical company's stock worth $373,000 after purchasing an additional 737 shares during the last quarter. Venturi Wealth Management LLC acquired a new stake in Agios Pharmaceuticals in the fourth quarter valued at $33,000. Finally, Swiss National Bank increased its holdings in Agios Pharmaceuticals by 1.0% in the fourth quarter. Swiss National Bank now owns 100,760 shares of the biopharmaceutical company's stock valued at $3,311,000 after purchasing an additional 1,000 shares during the period.

Agios Pharmaceuticals Stock Performance

Shares of Agios Pharmaceuticals stock traded down $0.97 during trading hours on Thursday, reaching $25.31. The company's stock had a trading volume of 773,656 shares, compared to its average volume of 711,908. The company has a market capitalization of $1.45 billion, a P/E ratio of 2.23 and a beta of 0.83. The stock's fifty day simple moving average is $31.54 and its two-hundred day simple moving average is $39.40. Agios Pharmaceuticals, Inc. has a one year low of $23.42 and a one year high of $62.58.

Remove Ads

Agios Pharmaceuticals (NASDAQ:AGIO - Get Free Report) last announced its quarterly earnings results on Thursday, February 20th. The biopharmaceutical company reported ($1.74) earnings per share for the quarter, missing the consensus estimate of ($1.69) by ($0.05). Agios Pharmaceuticals had a net margin of 1,845.92% and a negative return on equity of 2.51%. As a group, research analysts forecast that Agios Pharmaceuticals, Inc. will post -6.85 earnings per share for the current year.

Insider Activity at Agios Pharmaceuticals

In related news, Director Jacqualyn A. Fouse sold 7,497 shares of the stock in a transaction on Thursday, April 10th. The stock was sold at an average price of $25.90, for a total value of $194,172.30. Following the completion of the sale, the director now directly owns 149,220 shares of the company's stock, valued at approximately $3,864,798. This represents a 4.78 % decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. 4.93% of the stock is owned by insiders.

Wall Street Analyst Weigh In

A number of equities research analysts have commented on AGIO shares. HC Wainwright began coverage on Agios Pharmaceuticals in a research report on Monday, February 24th. They issued a "buy" rating and a $58.00 price target on the stock. Cantor Fitzgerald reiterated an "overweight" rating on shares of Agios Pharmaceuticals in a report on Wednesday, December 18th. Finally, StockNews.com downgraded shares of Agios Pharmaceuticals from a "hold" rating to a "sell" rating in a research report on Friday, February 14th. One analyst has rated the stock with a sell rating, four have given a hold rating and five have issued a buy rating to the stock. According to MarketBeat, the stock presently has an average rating of "Hold" and an average target price of $56.57.

Agios Pharmaceuticals Profile

Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.